Arvinas' PROTAC approach has several advantages over conventional drugs, including the potential to target "undruggable" proteins, achieve tissue-specific targeting, and cross the blood-brain barrier.

NEW HAVEN, Conn., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced ...

University of Pittsburgh School of Medicine scientists have developed drug candidates that early tests suggest could reverse HIV’s ability to escape detection by the immune system. The team’s research ...

Reducing the time and expense of engineering PROTAC degraders remains a significant challenge in the pharmaceutical industry. A PROTAC is composed of an E3 ligase ligand (E3-L), a protein of interest ...